0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Capitol Health Call |

Surrogate End Points Queried

Mike Mitka
JAMA. 2008;299(14):1657. doi:10.1001/jama.299.14.1657-a.
Text Size: A A A
Published online

Extract

The Government Accountability Office (GAO) will review a drug approval process used by the Food and Drug Administration (FDA) that evaluates safety and efficacy based on surrogate end points in clinical trials.

The review comes at the request of Sen Chuck Grassley (R, Iowa), who said March 4 that the FDA had approved several drugs that appeared to have little to no effect in protecting lives and improving health. Grassley singled out bevacizumab (Avastin, Genentech), rosiglitazone (Avandia, GlaxoSmithKline PLC), and ezetimibe/simvastatin (Vytorin, Merck/Schering-Plough Pharmaceuticals). Grassley said the FDA had approved the drugs based on their effectiveness in achieving surrogate end point goals (such as limiting tumor growth) without determining whether the drugs improved health.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Chapter 11.4. Surrogate Outcomes

Users' Guides to the Medical Literature
When Randomized Controlled Trials Have Contradicted Human Studies of Surrogate Endpoints

brightcove.createExperiences();